Catastrophic bilateral sudden sensorineural hearing loss following COVID-19

Michael Edwards, Jameel Muzaffar, Paresh Naik, Christopher Coulson

SUMMARY
Since December 2019, when it was first detected in Wuhan, the SARS-CoV-2 (COVID-19) has spread across the globe. The pandemic has had an unprecedented impact on the global population with >110 million confirmed cases and 2.5 million deaths. The most common initial symptoms of COVID-19 infection are cough, dyspnoea, fever, malaise and anosmia. Severe clinical manifestations include respiratory compromise, pneumonia, organ failure and death. There have been many other less common symptoms as a result of COVID-19 described in the literature, including significant rates of olfactory dysfunction. However, we believe there has been only one other previously documented cases of bilateral hearing loss.

Sudden sensorineural hearing loss is a relatively common presentation seen by otolaryngologists. It is defined as rapid hearing loss, ≥30 dB occurring over 3 consecutive days in three contiguous sound frequencies. The exact pathological process is yet to be fully characterised, though it is most commonly unilateral and commonly develops shortly following viral infection. Treatment typically consists of glucocorticoid steroids administered orally, via intratympanic injection or a combination of both routes though there are currently no standardised management of these patients.

Bilateral sudden sensorineural hearing loss (SSNHL) is rare, accounting for <2% of all cases. We describe a case of bilateral SSNHL in a 68-year-old patient who presented with profound hearing loss shortly after symptomatic infection with COVID-19, which at the time of publication is the first such case reported in the literature.

CASE PRESENTATION
A 68-year-old woman presented to her general practitioner with a 3-day history of sudden onset of profound bilateral hearing loss following a high fever and intense bilateral tinnitus the day before. This occurred on a background of recent COVID-19 infection. The patient initially developed high-grade fever and cough 10 days prior to onset of otologic symptoms. This prompted a COVID-19 PCR test on the same day which returned positive. For the period of time between COVID-19 diagnosis and the onset of otologic symptoms, the patient remained clinically healthy.

The patient had a medical history of non-alcoholic fatty liver disease, hypertension, insulin-dependent diabetes mellitus and dyslipidaemia. Their regular medications included aspirin 75 mg once daily, atorvastatin 20 mg once daily, atenolol 50 mg once daily, bendroflumethiazide 2.5 mg once daily, candesartan 4 mg once daily, humalog insulin 34 units at morning and 24 units at night and metformin 1 g two times a day. They had a pre-COVID-19 audiogram carried out in 2009, which was normal (figure 1).

On examination, both external auditory canals were healthy and the tympanic membranes were normal. A pure tone audiometry (PTA) found severe-profound sensorineural hearing loss in both ears (figure 2). An MRI of the internal auditory meati was not offered to this patient in keeping with guidelines published by the National Institute for Health and Care Excellence.

They were initially treated with a 7-day course of prednisolone 60 mg once daily and a left-sided intratympanic methylprednisolone (125 mg) injection. PTA was repeated 3 days later which revealed improvement of the left ear (figure 3). The decision was made to continue treatment with bilateral intratympanic methylprednisolone injections. Four days following this, further PTA was performed (figure 4). A third left-sided and second right-sided intratympanic methylprednisolone injection was administered which concluded medical management. The patient returned 1 week later for final audiogram testing (figure 5). The PTA values are summarised in table 1. This confirms a diagnosis of profound bilateral SSNHL.

TREATMENT
Treatment comprised of both oral and intratympanic steroid administration. At presentation, the patient commenced a 7-day course of prednisolone 60 mg once daily and received a 1 mL left-sided intratympanic methylprednisolone injection (125 mg/mL) which lead to an initial mild improvement in left-sided hearing. Following a total of two right-sided and three left-sided intratympanic steroid injections, serial PTA demonstrated a persistent and profound bilateral SSNHL.

DISCUSSION
The role of COVID-19 in hearing loss is scarcely documented and poorly understood. There is a considerable amount of on-going research to better characterise SSNHL, which aims to develop both diagnostic and management strategies. A systematic literature review was carried out using the PubMed database. The key words used were ‘coronavirus’, ‘COVID-19’, ‘hearing loss’, ‘sensorineural hearing loss’ and ‘SSNHL’. After the literature was screened, the following resulting publications were fully reviewed: a systematic review, one comparative study and nine case studies.
In November 2020, Maharaj and colleagues² published a systematic review of otologic dysfunction in patients with COVID-19, the first and only of its kind to date. They found just four documented cases of SSNHL related to COVID-19, none of which were bilateral in nature. Furthermore, they found two cases of unilateral sensorineural hearing loss and a single case of unilateral conductive hearing loss, the latter of which was presumed to be due to a middle ear effusion secondary to nasopharyngeal infection.

Although we describe the first recorded bilateral case, Koumpa and colleagues³ reported the first British case of unilateral SSNHL following COVID-19 in September 2020. The 45-year-old man suffered a severe infective course, requiring intubation and ICU support for 30 days. This was complicated further by bilateral pulmonary emboli, ventilator-associated pneumonia, pulmonary hypertension and anaemia. Although they did not receive any ototoxic medications, the patient then reported tinnitus and hearing loss 1 week after discharge from ICU. Following a 1-week course of oral prednisolone, this patient reported subjective improvement, and after three rounds of rescue intratympanic injections of 0.5 mL methylprednisolone (125 mg/mL) they showed no improvement on PTA.

In January 2021, Chern et al⁴ described an 18-year-old girl with bilateral SSNHL and associated COVID-19 infection. They were found to have bilateral intralabyrinthine haemorrhage (left more pronounced than right on MRI) 8 weeks after loss of hearing, and tested positive for COVID-19 IgG antibodies 10 weeks after the onset of symptoms. The authors attributed the otologic symptoms to COVID-19-associated coagulopathy and/or direct viral invasion of the labyrinth of cochlear nerve, though the case they report does not feature prodromal fever or tinnitus, and details positive IgG COVID-19 antibodies tested for 10 weeks after initial presentation with new onset loss of taste and olfaction. Both patients received steroids by both oral and intratympanic route, though unlike the case we describe, this patient saw gradual improvement in the right ear. This association between severity on MRI of the left ear versus the right ear, and the clinical course of worsening of the former and improvement of the latter seem to support a coagulopathic rather than direct invasion theory of pathogenesis.

There is new evidence that COVID-19 causes significant decline cochlear hair cell function, as documented by Mustafa.⁵ The comparative study of asymptomatic individuals with positive COVID-19 PCR found reduction in sensitivity to higher frequency PTA when compared with healthy controls. Perhaps, more importantly, the amplitude of transient-evoked otoacoustic emissions were significantly reduced in the test group, which possibly represents COVID-19 having a direct and deleterious effect on cochlear hair cells.

Owing to the fact that the disease process of SSNHL remains poorly understood it remains a topic undergoing extensive collaborative research within the otolaryngology community. The SeaSHel National Prospective Cohort Study, supported by INTEGRATE, the UK ENT Trainee Research Network and the National Institute for Health Research Clinical Research Network, is an on-going collaborative project which aims to establish a standardised patient pathway for those presented...
with SSNHL, develop methods to prognosticate those with the disease and to accurately elucidate the morbidity that it confers. Recently, a national prospective randomised controlled trial for treatment options for SSNHL was announced by INTER-GRATE,7 the largest of its kind thus far, which aims to determine the efficacy of steroid treatments given via different routes.

As the evidence of an association between COVID-19 and SSNHL increases, clinicians should consider the presence of hearing changes as part of their clinical assessment of these patients to ensure timely identification and treatment.

Table 1 Air conduction pure tone audiometry values summarised

<table>
<thead>
<tr>
<th>1 kHz (right, left)</th>
<th>2 kHz (right, left)</th>
<th>3 kHz (right, left)</th>
<th>4 kHz (right, left)</th>
<th>6 kHz (right, left)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Baseline</td>
<td>15, 20</td>
<td>15, 15</td>
<td>Not recorded</td>
<td>20, 30</td>
</tr>
<tr>
<td>2. Pretreatment</td>
<td>100, 110</td>
<td>90, 110</td>
<td>90, 110</td>
<td>95, 110</td>
</tr>
<tr>
<td>3. Following oral and IT steroid treatment</td>
<td>105, 75</td>
<td>100, 80</td>
<td>90, 85</td>
<td>90, 85</td>
</tr>
<tr>
<td>4. Following second IT treatment</td>
<td>105, 110</td>
<td>105, 100</td>
<td>100, 95</td>
<td>100, 100</td>
</tr>
<tr>
<td>5. Following third IT treatment</td>
<td>90, 110</td>
<td>95, 100</td>
<td>90, 90</td>
<td>85, 105</td>
</tr>
</tbody>
</table>

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD Jameel Muzaffar http://orcid.org/0000-0003-3065-0269

REFERENCES